Effects of paclitaxel and carboplatin on quality of life and survival in patients with advanced non-small-cell lung cancer

Journal of the Medical Association of Thailand

Volumn 83, Issue 9, 2000, Pages 1059-1067

  Ratanatharathorn, Vorachai ^a   Sirachainan, Ekapob ^a   Jirajarus, Manmana ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Carboplatin; Chemotherapy; Non small cell lung cancer; Paclitaxel; Quality of life

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE;

EID: 0033662441     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41.
2. Bunn PA. The treatment of non-small-cell lung cancer : Current prospectives and controversies, future directions. Semin Oncol 1994;21:49-54.
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer : A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
4. Le Lorier J, Gregoire G, Benhaddad A. et al. Discrepancies between meta-analyses and subsequent Iarge randomized, controlled trials. N Engl J Med 1997;337:536-42.
5. Lilenbaum RC, Green MR. Novel chemotherapeutic agent in the treatment of non-small-cell lung cancer. J Clin Oncol 1993;11:1391-402.
6. Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbalone, and piroxantrone in stage IV non-small-cell lung cancer : The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993;85:388-94.
7. Murphy WK, Fossellan FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-8.
8. Langer CL, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer : A phase II toxicity, response and survival analysis. J Clin Oncol 1995;13:1860-70.
9. Greco FA, Hainsworth JD. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small-cell lung cancer : Results of a multicenter Phase II trial. Semin Oncol 1997; 24:12-7.
10. Laohavinij S, Maoleekoonpairoj S, Cheirsilpa A, et al. Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer. Lung Cancer 1999;26:175-85.
11. Silvestri G, Pritchard R, Gilbert Welch H, et al. Preference for chemotherapy in patients with advanced non-small-cell lung cancer : Descriptive study based on scripted interviews. Br Med J 1998;317:771-5.
12. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-41.
13. Padilla GV, Presant C, Grant M, et al. Quality of life index for patients with cancer. Res Nurs Health 1983;6:117-26.
14. Hanucharurnkul S. Predictors of self-care in cancer patients receiving radiotherapy. Cancer Nursing 1989;12 : 21-6.
15. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297.
16. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211-8.
17. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer : How much benefit is enough? J Clin Oncol 1993; 11:1866-72.
18. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small-cell lung cancer : A meta-analysis. Lancet 1993;342:19-21.
19. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer : A phase II trial. J Clin Oncol 1996; 14:2054-60.
20. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995;71:366-70.
21. de Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychologic and physical distress in cancer patients : Structure and application of Rotterdam symptom checklist. Br J Cancer 1990: 62:1034-8.
22. Bergman B, Aaronson NK, Ahmedzai S. et al. The EORTC QOL-LC13 : A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trial. Eur J Cancer 1994;30A:635-42.
23. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 1995: 13:1904-11.
24. Bonomi P, Kim K, Chang A. et al. Phase III Trial comparing etoposide (E) cisplatin (C) versus taxolcisplatin in advanced non-small-cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) Trial. Proc Am Soc Clin Oncol 1996;15:A1145, p382.
25. Sanders C, Egger M, Donovan J, et al. Reporting on quality of life in randomized controlled trials : Bibliographic study. Br Med J 1998;317:1191-4.
26. Tester WJ, Jin PY, Reardon DH. et al. Phase II study of patients with metastatic non-small-cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer 1997;79:724-9.
27. Cullen MH, Billingham LJ, Woodroffe CM. et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer : Effect on survival and quality of life. J Clin Oncol 1999;17: 3188-94.
28. Han JY, Kim HK, Choi BG, et al. Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide, and cisplatin) chemotherapy in advanced non-small-cell lung cancers (NSCLC). Jpn J Clin Oncol 1998;28:749-53.
29. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale : Development and validation of the general measure. J Clin Oncol 1993;11 : 570-9.
30. Kemmler G, Holzner B, Kopp M. et al. Comparison of two quality-of-life instruments for cancer patients : The functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer quality-of-life questionnaire-C30. J Clin Oncol 1999;17: 2932-40.
31. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 1998;16:3662-73.
32. Cella DF. Quality of life outcomes : Measurement and validation. Oncology 1996;10:232-44.
33. Guyatt GH, Jaeschke R, Feeny DH, et al. Measurements in clinical trials: choosing the right approach. in Spiker B (ed) Quality of life and pharmacoeconomics in clinical trials. (2nd ed). New York, NY: Lippincott-Raven 1996:41-8.
34. Hahn EA, Webster KA, Cella D, et al. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: Problem and solutions. Statis Med 1998; 17: 547-59.